User:Mr. Ibrahem/Crizanlizumab

Crizanlizumab, sold under the brand name Adakveo among others, is a medication used to treat sickle cell disease. Specifically it is used to reduce the frequency of vaso-occlusive crisis in people over 15 years old. It is given by injection into vein.

Common side effects include joint pain, nausea, fever, and abdominal pain. Other side effects may include infusion reactions. Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to and blocks P-selectin, decreasing the attaching of cells to the inside of blood vessels.

Crizanlizumab was approved for medical use in the United States in 2019 and Europe in 2020. In the United Kingdom 100 mg costs the NHS about £1,000 as of 2021. This amount in the United States is about 2,400 USD.